Knight Therapeutics and Triumvira Immunologics Triumphantly Announce Secured Bridge Loan & License Agreement
MONTREAL and AUSTIN, Texas and HAMILTON, Ontario, Feb. 20, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight“), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative pharmaceutical products, today announced it has entered into a secured loan and exclusive License Agreement with privately-held Triumvira Immunologics Inc. (“Triumvira“). The US$5 million secured […]
Knight Signs GUD (Bueno) Latin American Strategic Funding Deal with Moksha8
MONTREAL and BERWYN, Pa., Feb. 18, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight“), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription pharmaceutical products and Moksha8 Inc. (“Moksha8“), a specialty pharmaceutical company focused on licensing and marketing innovative and established therapeutics in Latin America, today announced the closing of […]
Knight Therapeutics Runs with Exclusive Canadian License to Puma’s NERLYNX®
MONTREAL, Jan. 11, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products, today announced it has entered into an exclusive License Agreement with Puma Biotechnology, Inc. (NASDAQ: PBYI) (“Puma“) granting Knight the exclusive right to commercialize NERLYNX® (neratinib) […]
Knight Therapeutics Announces Canadian Regulatory Approval for ILUVIEN®
MONTREAL, Nov. 26, 2018 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, today announced that Health Canada has approved ILUVIEN® for the treatment of diabetic macular edema (DME). ILUVIEN is a fluocinolone acetonide sustained release non-biodegradable intravitreal implant used to treat DME in patients who have been previously treated with a […]
Knight Therapeutics Reports Third Quarter 2018 Results
MONTREAL, Nov. 08, 2018 — Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a Canadian specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2018. Q3 2018 Highlights Financials Revenues were $3,220, an increase of $1,360 or 73% over prior period. Net income was $12,930, an increase of $9,337 or 260% over prior […]
Notice of Knight Therapeutics' Third Quarter 2018 Results Conference Call
MONTREAL, Nov. 01, 2018 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its third quarter 2018 financial results on Thursday, November 8th, 2018 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in […]
Knight Therapeutics Announces the Canadian launch of PROBUPHINE™ for Opioid Use Disorder
MONTREAL, Oct. 29, 2018 — Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today the commercial availability of PROBUPHINE™ (buprenorphine hydrochloride subdermal implant), for the management of opioid dependence in patients clinically stabilized on no more than 8 mg of sublingual buprenorphine in combination with counseling and psychosocial support1. Knight has […]
Knight to Present at the Cantor Fitzgerald Global Healthcare Conference in New York City
MONTREAL, Sept. 25, 2018 — Knight Therapeutics Inc. (TSX: GUD), a leading Canadian specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Financial Officer, will be presenting at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, 2018 at 12:15 pm ET, at the Intercontinental New York Barclay Hotel in New York […]
Knight Therapeutics and Jaguar Health Announce Strategic Partnership
Knight receives license to Mytesi® and related products in Canada and Israel MONTREAL and SAN FRANCISCO, Sept. 24, 2018 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a Canadian-based specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative prescription and over-the-counter pharmaceutical products, and Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a […]
Knight to Participate at the Morgan Stanley Global Healthcare Conference in New York City
MONTREAL, Sept. 06, 2018 — Knight Therapeutics Inc. (TSX: GUD), a leading Canadian specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Financial Officer, will participate in a fireside chat at the 16th Annual Morgan Stanley Global Healthcare Conference on Thursday, September 13, 2018 at 3:30 pm ET at the Grand Hyatt in […]
